更昔洛韦-纤维蛋白胶-羊膜复合物的缓释特性  

Release characteristics of ganciclovir-fibrin glue-amniotic membrane complex

作　　者：蔡明铭[1] 赵敏[2] 

机构地区：[1]重庆市第九人民医院眼科,重庆市400700 [2]重庆医科大学附属第一医院眼科,重庆市400016

出　　处：《中国组织工程研究与临床康复》2011年第3期419-422,共4页Journal of Clinical Rehabilitative Tissue Engineering Research

基　　金：重庆市科技攻关项目(csts2008ac0086);题目:胶联羊膜制品的开发及临床前研究~~

摘　　要：背景:近年来,纤维蛋白胶作为药物缓释载体的作用日益受到人们的重视。更昔洛韦是一种有效治疗病毒性角膜炎的广谱抗病毒药物。故选择此药物进行胶联羊膜缓释药膜的初步探索。目的:观察更昔洛韦-纤维蛋白胶-羊膜复合物的缓释特性,探索临床治疗病毒性角膜炎的新方法。方法:体外实验:将纤维蛋白胶与更昔洛韦混合后与羊膜黏合,制成更昔洛韦-纤维蛋白胶-羊膜复合物,观察更昔洛韦的体外缓释情况。体内实验:新西兰大白兔右眼为实验组在兔眼表作更昔洛韦-纤维蛋白胶-羊膜移植;左眼为对照组滴1g/L更昔洛韦眼液,每2h滴100μL。应用高效液相色谱法测试不同时间点房水中更昔洛韦的质量浓度。结果与结论:体外释放实验显示,24h后更昔洛韦的累计释放率为(45.67±5.32)%,48h后为(63.42±4.68)%,96h后释放趋于平衡。动物实验表明:实验组房水中更昔洛韦浓度随时间逐渐降低。第1天时,实验组房水药物浓度显著高于对照组(P<0.01)。第2,3天,实验组房水更昔洛韦质量浓度稍高,与对照组比较差异无显著性意义。第4,5天,实验组房水药物浓度低于对照组(P<0.05)。结果提示,在体外及体内条件下,更昔洛韦-纤维蛋白胶-羊膜复合物均具有良好的缓释特性,可望成为治疗病毒性角膜炎的新手段。BACKGROUND： In recent years, fibrin glue as a drug delivery carrier, has been attracting a growing attention. Ganciclovir is an effective broad-spectrum antiviral drug of viral keratitis. Therefore, we choose this drug in the initial exploration and research of drug delivery-fibrin glue-amniotic membrane. OBJECTIVE： To study the release characteristics of ganciclovir-fibrin glue-amniotic membrane and to explore a new method for clinical treatment of viral keratitis. METHODS： In vitro study： fibrin glue compounded with ganciclovir and amniotic membrane to prepare the ganciclovir-fibrin glue-amniotic membrane complex and the in vitro release characteristics of ganciclovir was studied. In vivo study： ganciclovir-fibrin glue-amniotic membrane complex was transplanted on right eyes of New Zealand rabbits as experimental group, and 1 g/L ganciclovir dropped into left eye, 100 μL was given in 5 eyes every 2 hours as the control. The ganciclovir concentration in the aqueous humors was assayed by high performance liquid chromatography. RESULTS AND CONCLUSION： In vitro release study revealed that the accumulative release rate of ganciclovir was （45.67±5.32）% 24 hours after incubation and rose to （63.42±4.68）% 48 hours later. The release process went to a balance condition 96 hours later. Animal indicated that the ganciclovir level in aqueous gradually reduced along with time. The drug level was significantly higher for experimental group than control at 1 day （P 0.05）; during 2-3 days, the drug level in aqueous of experimental group was higher than control group without significant differences; the ganciclovir level in aqueous of experimental group was lower than that of control group at 4-5 days （P 0.05）. The ganciclovir-fibrin glue-amniotic membrane complex has a good sustained release property both in vitro and in vivo, it may be a new treatment of viral keratitis.

关 键 词：缓释 纤维蛋白胶 羊膜 更昔洛韦 病毒性角膜炎 

分 类 号：R318[医药卫生—生物医学工程]